In the study of colorectal cancer, celecoxib can directly activate NF-κB and its dependent gene transcription without relying on COX inhibition, activate the Fas/FasL signaling pathway to mediate cell killing, and also inhibit protein kinase B phosphorylation and promote cell apoptosis (Han et al., 2000). Here, NFKB1 is linked to colorectal cancer.